Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (PIONEER)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 16, 2010
Last updated: August 5, 2011
Last verified: August 2011

The purpose of this study is to study the changes in protein in lung cells of Asian patients with advanced non small cell lung cancer.

Condition Intervention
Non Small Cell Lung Cancer
Procedure: Testing for mutation status

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: A Molecular Epidemiology Study in Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) of Adeno Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • EGFR mutation status of Asian patients with advanced NSCLC [ Time Frame: Samples will be tested after informed consent. Mutation results will be available within 1-3 weeks. ] [ Designated as safety issue: No ]

Estimated Enrollment: 1270
Study Start Date: September 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
EGFR mutation testing
Procedure: Testing for mutation status
EGFR mutation test

Detailed Description:

A molecular epidemiology study in Asian patients with advanced NSCLC of adeno histology to assess EGFR mutation status.


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytologically confirmed advanced Non small cell lung cancer of adeno histology NSCLC treatment naive Availability of cancer tissue or cytology sample

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study Previous enrollment in the present study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01185314

  Show 36 Study Locations
Sponsors and Collaborators
Study Director: Guy Yeoman, MBBS, MFPM AstraZeneca
Study Chair: Robin Meng, MD, PhD AstraZeneca Taiwan
Principal Investigator: Yang Pan-Chyr, MD, PhD National Taiwan University College of Medicine
  More Information

No publications provided

Responsible Party: Gerard Lynch, AstraZeneca Identifier: NCT01185314     History of Changes
Other Study ID Numbers: D7913L00086
Study First Received: August 16, 2010
Last Updated: August 5, 2011
Health Authority: China: Ethics Committee
Hong Kong: Ethics Committee
India: Central Drugs Standard Control Organization
India: Indian Council of Medical Research
India: Ministry of Health
India: Ministry of Science and Technology
India: Institutional Review Board
Philippines: Bureau of Food and Drugs
Taiwan: Department of Health
Taiwan: Institutional Review Board
Thailand: Ethical Committee

Keywords provided by AstraZeneca:
NSCLC, EGFR mutation

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on November 20, 2014